| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d5fe74855697fef20a2e98a9b005db19 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-57
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-34
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P15-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P15-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07J1-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07J7-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-565
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-57 |
| filingDate |
1996-10-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8a8fed767d69d1c2157963bc1f3a4353
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9b100c16774544ddaf119876ceda993d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_94a428e15d41ef04e59274c1331eef3d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2216ce109fa8a0b83556e33eb1c9873a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a73328ac4106cc73448b5be532876e79
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_774e7e515051e2cfd6c01f4f3db1991e |
| publicationDate |
1997-06-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-H09169649-A |
| titleOfInvention |
Multi-stage dispensing for contraception |
| abstract |
(57) 【Abstract】 PROBLEM TO BE SOLVED: To realize safety of contraception in the course of cycle and to improve cyclic bleeding behavior in the case of low estrogen dose and low gestagen dose compared with conventional ovulation inhibitors. Providing hormonal contraceptives based on natural estrogen. In a multi-stage preparation for contraception, the first stage consists of 2 to 4 daily dose units, all daily dose units containing exclusively natural estrogen as an active substance and the second stage Consists of 22 to 16 daily dose units, In this case all daily dosage units contain as an agent a combination of at least one natural estrogen and at least one synthetic or natural gestagen, The stages consist of 2 to 4 daily dose units, in which case all daily dose units contain exclusively natural estrogen as the active substance and another stage consists of 2 to 4 daily dose units. In all cases a multi-stage preparation for contraception, characterized in that all daily dosage units contain a placebo which is of no pharmaceutical concern. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2009511526-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2013047269-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-4908399-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2007533681-A |
| priorityDate |
1995-10-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |